Abstract
The iLet Bionic Pancreas system can improve glycemia in individuals with type 1 diabetes with its simple interface, setup, and maintenance, making it practical for use in the primary care setting and via telehealth (TH). This multisite, random-order crossover trial included 40 adults with type 1 diabetes who received care either from an endocrinology or a primary care clinic and were seen either in person or via TH. Of these 40 participants, 97% achieved an average glucose (AG) <183 mg/dL, and 64% achieved an AG <154 mg/dL. These results suggest that the system can be initiated effectively by primary care providers and via TH, potentially expanding access to this technology to a broad population, including individuals who cannot easily access subspecialty diabetes care.